MammaPrint Molecular Diagnostics on Formalin-Fixed, Paraffin-Embedded Tissue.

Publication Name: The Journal of Molecular Diagnostics

Author(s): Sapino A, Roepman P, Linn SC, Snel MHJ, Delahaye LJMJ, van den Akker J, Glas AM, Simon IM, Barth N, de Snoo FA, van 't Veer LJ, Molinaro L, Berns EMJJ, Wesseling J, Riley LB, Anderson D, Nguyen B, Cox

MammaPrint, a prognostic 70-gene profile for early-stage breast cancer, has been available for fresh tissue. Improvements in RNA processing have enabled microarray diagnostics for formalin-fixed, paraffin- embedded (FFPE) tissue. Here, we describe method optimization, validation, and performance of MammaPrint using … Continued

Agendia Announces Presentation of Data Highlighting Symphony Suite of Genomic tests (MammaPrint, BluePrint, and TargetPrint) at San Antonio Breast Cancer Symposium

Publication Name: Press Release

Ten Scientific Posters Document Study Results on Second-Generation Symphony Suite, Containing Multi-Gene Signatures to Provide Molecular Subtyping IRVINE, CA and AMSTERDAM, THE NETHERLANDS, December 9, 2013 – New breast cancer research incorporating  the SymphonyTM suite of genomic tests (MammaPrint®, BluePrint® … Continued

Molecular subtyping improves stratification of patients into diagnostically more meaningful risk groups

Publication Name: Cancer Research

Author(s): Massimo Cristofanilli, Karen Kaul, Mary Turk, JoEllen Weaver, Jelle Wesseling, Lisette Stork-Sloots, Femke de Snoo, Katharine Yao

This retrospective study showed that Molecular Subtyping of early breast cancers using Mammaprint and BluePrint leads to reclassification of 25% (51/208) of tumors with potential therapeutic and prognostic implications: – 39% of clinical HER-2 disease should have been treated with … Continued

Performance Characteristics of the MammaPrint Breast Cancer Diagnostic Gene Signature

Publication Name: Personalized Medicine

Author(s): Leonie JM Delahaye, Diederik Wehkamp, Arno N Floore, Rene Bernards, Laura J van‘t Veer1 & Annuska M Glas

The analytical performance of multigene signatures depends on many parameters, including precision, repeatability, reproducibility and intratumor heterogeneity. Indicators such as sensitivity, specificity, positive predictive value and negative predictive value are typically used to define the clinical performance of a diagnostic … Continued

Multiple International Breast Cancer Guidelines Confirm Use of Agendia Tests for Prognostic, Predictive Information in Cancer Treatment Decisions

Publication Name: Press Release

Important Role of Molecular Subtyping in Determining the Need for Chemotherapy also Cited IRVINE, CA, and AMSTERDAM, THE NETHERLANDS, September 9, 2013 – Agendia, a leader in molecular cancer diagnostics, today announced that multiple established international breast cancer treatment guidelines … Continued

Estrogen receptor splice variants as a potential source of false-positive estrogen receptor status in breast cancer diagnostics

Publication Name: Breast Cancer Research and Treatment

Author(s): Groenendijk, Wilbert Zwart, Arno Floore, Stephanie Akbari, Rene Bernards

It is well established that only estrogen receptor (ER)-positive tumors benefit from hormonal therapies. We hypothesized that a subgroup of breast cancer patients expresses estrogen receptor a (ERa), but fails to respond to hormonal therapy due to the expression of … Continued

Molecular subtyping of early-stage breast cancer identifies a group of patients who do not benefit from neoadjuvant chemotherapy

Publication Name: Breast Cancer Research and Treatment

Author(s): Stefan Glück, Femke de Snoo, Justine Peeters, Lisette Stork-Sloots, George Somlo

The aim of this study was to analyze the correlation between the pathologic complete response (pCR) rate after neoadjuvant chemotherapy and long-term outcome (distant metastases-free survival [DMFS]) in patients with early-stage breast cancer using BluePrint and MammaPrint molecular subtyping versus … Continued